Showing 137 news articles about Injectable & long-acting HIV treatment

Filters Content type: Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

Editor's pick
Merck press release
14 December 2021
Injectable & long-acting HIV treatment

Long-Acting HIV Therapy Hits a Snag

Editor's pick
POZ
9 December 2021
Injectable & long-acting HIV treatment

The Medicines Patent Pool and the University of Washington sign a licence agreement for an investigational long-acting injectable drug combination candidate for HIV

Editor's pick
Medicines Patent Pool
9 December 2021
Injectable & long-acting HIV treatment

England & Wales: NICE approves first long-acting injectable HIV-1 treatment

Editor's pick
National Institute for Health and Care Excellence
18 November 2021
Injectable & long-acting HIV treatment

Cabenuva Works Well Regardless of Body Weight

Editor's pick
POZ
5 November 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
Injectable & long-acting HIV treatment

Cabotegravir (Vocabria®) is accepted for use within NHSScotland

Editor's pick
Scottish Medicines Consortium
11 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
Injectable & long-acting HIV treatment

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Editor's pick
GlobeNewswire
22 September 2021
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Editor's pick
GlobeNewswire
20 September 2021
Injectable & long-acting HIV treatment

New Guideline for Replacement ART: CAB/RPV LA Not for Everyone

Editor's pick
Medscape (requires free registration)
3 August 2021
Injectable & long-acting HIV treatment

A Change of Pace

Editor's pick
POZ
2 August 2021
Injectable & long-acting HIV treatment

Failed viral suppression in CAB/RPV linked to 3 Risk Factors

Editor's pick
Medscape (requires free registration)
28 July 2021
Pharmaceutical industry

GSK puts long-acting injectables at heart of HIV growth plans, downplays threat of oral rival from Gilead and Merck

Editor's pick
FiercePharma
29 June 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
Injectable & long-acting HIV treatment

GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal

Editor's pick
FiercePharma
23 June 2021
Injectable & long-acting HIV treatment

Long-acting Injectables: when will they be available in the UK?

Editor's pick
UK-CAB
21 June 2021
Injectable & long-acting HIV treatment

Long-Acting ART Rollout: 3 Considerations for Clinicians

Editor's pick
TheBodyPro
26 May 2021
Injectable & long-acting HIV treatment

GlaxoSmithKline's ViiV preps doctors ahead of Cabenuva's patient marketing push

Editor's pick
FiercePharma
26 May 2021
Injectable & long-acting HIV treatment

Enthusiasm for Once-Monthly Cabenuva Is High—But There Are Questions, Too

Editor's pick
TheBody
18 May 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
TB treatment

Should TB Treatment Move into Long-Acting Injectables?

Editor's pick
Contagion Live
11 March 2021
Injectable & long-acting HIV treatment

ViiV Seeks FDA Approval for Cabenuva Dosed Every 2 Months for HIV

Editor's pick
Monthly Prescribing Reference
26 February 2021